UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 11) *

Arch Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

03939W 208 (CUSIP Number)

Michael Parker 1928 East Highland Avenue, Suite F104-558 Phoenix, Arizona 85016 (480) 717-0911

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 31, 2023

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b) ⊠ Rule 13d-1(c)

☐ Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

1.	NAMES OF REPORTING PERSONS		
	Michael Parker		
2.	K THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)		
	(a) □ (b) ⊠		
3.	SEC USE ONLY		
4. CITIZENSHIP OR PLACE OF ORGANIZATION		ENSHIP OR PLACE OF ORGANIZATION	
	United States		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			
	5.	SOLE VOTING POWER	
		8,405 shares of Common Stock (see Appendix A)	
	6.	SHARED VOTING POWER	
	7.	205,124 shares of Common Stock (see Appendix A) SOLE DISPOSITIVE POWER	
		8,405 shares of Common Stock (see Appendix A)	
	8.	SHARED DISPOSITIVE POWER	
9.	AGGR	205,124 shares of Common Stock (see Appendix A) EEGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
213,529 shares of Common Stock (see Appendix A)		9 shares of Common Stock (see Appendix A)	
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (se instructions) \boxtimes		
11.	PERCI	ENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	4.50% (see Appendix A)		
12.	TYPE	OF REPORTING PERSON (see instructions)	
	IN		

SCHEDULE 13G

Page 2 of 6 Pages

CUSIP No. 03939W 208

CUSIP No. 03939W 208			SCHEDULE 13G	Page 3 of 6 Pages
Item 1.				
	(a)	Name of Issuer Arch Therapeutics, Inc.		
(b) Address of Issuer's Principal Executive Offices 235 Walnut Street, Suite 6, Framingham, MA 01702				
	(a)	Name of Person Filin This Statement is file		
	(b)		pal Office or, if none, residence o's address is 1928 East Highland Avenu	ne, Suite F104-558, Phoenix, Arizona
	(c)	Citizenship The Reporting Person	n is a citizen of the United States.	
	(d)	Title of Class of Secu Common Stock, par v	urities value \$0.001 per share	
(e) CUSIP Number 03939W 208				
Item 3. If this statement is filed pursua a:		atement is filed pursua	nt to §§240.13d-1(b) or 240.13d-2(b) or	(c), check whether the person filing is
	(a)	Broker or dealer regis	stered under section 15 of the Act (15 U.	S.C. 78o).
	(b)	Bank as defined in se	ction 3(a)(6) of the Act (15 U.S.C. 78c).	
(c) Insurance company as		Insurance company as	s defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	Investment company 80a-8).	registered under section 8 of the Investment	nent Company Act of 1940 (15 U.S.C.
	(e)	An investment advise	er in accordance with §240.13d-1(b)(1)(i	i)(E);
	(f)	An employee benefit	plan or endowment fund in accordance	with §240.13d-1(b)(1)(ii)(F);
	(g)	A parent holding com	npany or control person in accordance w	ith §240.13d-1(b)(1)(ii)(G);
	(h)	A savings association 1813);	s as defined in Section 3(b) of the Feder	ral Deposit Insurance Act (12 U.S.C.

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

(i)

(j)

CUSIP No. 03939W 208	SCHEDULE 13G	Page 4 of 6 Pages

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: See Row 9 of the cover page for each Reporting Person.
- (b) Percent of class: See Row 11 of the cover page for each Reporting Person.
- (c) Number of shares as to which the person has:
 - Sole power to vote or to direct the vote: See Row 5 of the cover page for each Reporting Person.
 - (ii) Shared power to vote or to direct the vote: See Row 6 of the cover page for each Reporting Person
 - (iii) Sole power to dispose or to direct the disposition of: See Row 7 of the cover page for each Reporting Person.
 - (iv) Shared power to dispose or to direct the disposition of: See Row 8 of the cover page for each Reporting Person.

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box^* .

Instruction. Dissolution of a group requires a response to this item.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable

Item 8. Identification and Classification of Members of the Group.

Not applicable

Item 9. Notice of Dissolution of Group.

Not applicable

-	CUSIP No. 03939W 208	SCHEDULE 13G	Page 5 of 6 Pages
١,	CUSIF NO. 03939 W 200	SCHEDULE 130	rage 3 of 6 rages

Item 10. Certification.

(a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

(b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 19, 2024	
/s /Michael Parker	
Signature	
Michael Parker	
Name/Title	

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

CUSIP No. 03939W 208	SCHEDULE 13G	Page 6 of 6 Pages
CUSH NO. 03939 W 208	SCHEDULE 13G	1 age 0 01 0 1 ages

APPENDIX A

The Reporting Person owns outright 8,405 shares. The Reporting Person also is the spouse of Ana Parker, who owns outright 205,124 shares. Because the Reporting Person shares with Mrs. Parker the voting and dispositive power over these 205,124 shares, the Reporting Person may be deemed to be the beneficial owner of these shares as well. As a result, the Reporting Person may be deemed to be the beneficial owner of a total of 213,529 shares.

The Reporting Person disclaims any beneficial ownership of any of the 23,438 shares of Common Stock that may be acquired upon the exercise of Series K Warrants (which expire August 17, 2026) held by him, and any of the following shares that may be acquired by Ana Parker (his spouse) upon the exercise of the following warrants issued in her name: 17,143 shares of Common Stock that may be acquired upon the exercise of Series I Warrants (which expire October 18, 2024), 48,290 shares of Common Stock that may be acquired upon the exercise of a Warrant dated July 6, 2022 (which expire July 6, 2027), 82,465 shares of Common Stock that may be acquired upon the exercise of a Warrant dated August 31, 2023 (which expires August 31, 2028), and 549,486 shares of Common Stock that may be acquired upon the exercise of a Warrant dated August 31, 2023 (which expires August 31, 2028), as all such warrants cannot be exercised until such time as the holder would not beneficially own, after such exercise, more than 4.99% of the outstanding shares of Common Stock; provided, however, that the holder may increase (up to 9.99%), or decrease, the preceding percentage limitation, provided that no increase will become effective until sixtyone (61) days after the holder's delivery of notice of such increase. As of the date of this Schedule 13G, no notice of any increase in the percentage ownership limitation described in the preceding sentence has been given.

The Reporting Person also disclaims any beneficial ownership of any of the 51,042 shares of Common Stock issuable upon the conversion of the outstanding principal of and accrued interest on a Series 3B Subordinated Convertible Note, and any of the 52,517 shares of Common Stock issuable upon the conversion of the outstanding principal of and accrued interest on a Senior Secured Convertible Promissory Note, as such Notes cannot be converted until such time as the holder would not beneficially own, after such conversion, more than 4.99% of the outstanding shares of Common Stock; provided, however, that the holder may increase (up to 9.99%), or decrease, the preceding percentage limitation, provided that no increase will become effective until sixty-one (61) days after the holder's delivery of notice of such increase. As of the date of this Schedule 13G, no notice of any increase in the percentage ownership limitation described in the preceding sentence has been given.

In computing the ownership percentages set forth herein, the Reporting Person used the figure of 4,742,363 outstanding shares of Common Stock, which was provided to the Reporting Person by Issuer upon the Reporting Person's request.